RF_ID |
Disease Name |
2ndClass |
3rdClass |
4thClass |
Species |
RF_Name |
Association |
Condition |
PMID |
1890 |
Amyotrophic Lateral Sclerosis |
Medical methods |
Medicines |
lipid-lowering drugs |
Human |
HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase (HMGCR) inhibitors |
RF |
|
37688479 |
902 |
Alzheimer's Disease |
Medical methods |
Medicines |
Antidiabetic |
Human |
Glucagon-like peptide 1 (GLP-1) agonists |
PF |
|
35128745 |
442 |
Alzheimer's Disease |
Medical methods |
Medicines |
Antidiabetic |
Human |
metformin |
PF |
Type 2 diabetes mellitus (T2DM) |
36109050 |
2528 |
Parkinson disease |
Medical methods |
Medicines |
anticholinergic drugs |
Human |
anticholinergic drugs |
RF |
|
37357543 |
1468 |
Parkinson disease |
Medical methods |
Medicines |
Neuroleptics |
Human |
antidepressants |
RF |
|
35748105 |
919 |
Parkinson disease |
Medical methods |
Medicines |
targeted medicine |
Human |
LRRK2 inhibition |
PF |
|
35675433 |
1458 |
Alzheimer's Disease |
Medical methods |
Medicines |
Antidiabetic |
Human |
insulin |
RF |
Type 2 diabetes mellitus (T2DM) |
37095270 |
1465 |
Alzheimer's Disease |
Medical methods |
Medicines |
Antidiabetic |
Human |
Pioglitazone |
RF |
Type 2 diabetes mellitus (T2DM) |
37095270 |
1459 |
Parkinson disease |
Medical methods |
Medicines |
Neuroleptics |
Human |
anxiolytics |
RF |
|
35748105 |
484 |
Alzheimer's Disease |
Medical methods |
Medicines |
Neuroleptics |
Human |
anxiolytics |
PF |
|
35196953 |
1831 |
Alzheimer's Disease |
Medical methods |
Medicines |
Antihypertensive |
Human |
hypertension medication |
RF |
|
35196953 |
1836 |
Alzheimer's Disease |
Medical methods |
Medicines |
Neuroleptics |
Human |
antipsychotics |
RF |
|
35196953 |
1779 |
Alzheimer's Disease |
Medical methods |
Medicines |
Analgesic and anti-inflammatory drugs |
Human |
Muscle relaxant |
RF |
|
36641664 |
1778 |
Alzheimer's Disease |
Medical methods |
Medicines |
Analgesic and anti-inflammatory drugs |
Human |
Muscle relaxant |
RF |
|
36641664 |
1775 |
Alzheimer's Disease |
Medical methods |
Medicines |
Analgesic and anti-inflammatory drugs |
Human |
Muscle relaxant |
RF |
|
36641664 |
1446 |
Tuberous sclerosis complex |
Medical methods |
Medicines |
|
Human |
administration of multiple antiepileptic drugs |
RF |
|
20113608 |
761 |
Amyotrophic Lateral Sclerosis |
Medical methods |
Medicines |
Antidiabetic |
Human |
antidiabetics |
PF |
|
32097525 |
551 |
Parkinson disease |
Medical methods |
Medicines |
|
Human |
anti-histamines |
PF |
|
34494887 |
1776 |
Alzheimer's Disease |
Medical methods |
Medicines |
Neuroleptics |
Human |
benzodiazepine and related drug (BZDR) |
RF |
|
29851063 |
2474 |
Progressive Supranuclear Palsy |
Medical methods |
Medicines |
|
Human |
beta-blocker use |
RF |
|
31420308 |
3399 |
Parkinson disease |
Medical methods |
Medicines |
|
rat |
cinnarizine(a calcium antagonist that produces human parkinsonism) |
RF |
(a calcium antagonist that produces human parkinsonism) |
15993444 |
870 |
Alzheimer's Disease |
Medical methods |
Medicines |
Analgesic and anti-inflammatory drugs |
mice |
dexibuprofen (DXI) |
PF |
|
34294142 |
401 |
Parkinson disease |
Medical methods |
Medicines |
Antidiabetic |
Human |
Dipeptidyl peptidase-4 (DPP4) inhibitors |
PF |
|
33895825 |
397 |
Parkinson disease |
Medical methods |
Medicines |
Antidiabetic |
Human |
Dipeptidyl peptidase-4 (DPP4) inhibitors |
PF |
in diabetic patients |
38110464 |
1884 |
Parkinson disease |
Medical methods |
Medicines |
|
Human |
duration of exposure to levodopa |
RF |
|
23836370 |
1885 |
Parkinson disease |
Medical methods |
Medicines |
|
Human |
duration of exposure to levodopa |
RF |
|
23836370 |
819 |
Amyotrophic Lateral Sclerosis |
Medical methods |
Medicines |
|
Human |
Duration of OCP(oral contraceptive) use (per year) |
PF |
female |
28835399 |
519 |
Alzheimer's Disease |
Medical methods |
Medicines |
|
Human |
Estrogen-replacement therapy |
PF |
postmenopausal women |
9566385 |
3102 |
Frontotemporal Dementia |
Medical methods |
Medicines |
|
Human |
Excluding specific neuroprotective supplements |
RF |
after onset of disease |
33138082 |
2611 |
Multiple System Atrophy |
Medical methods |
Medicines |
|
Human |
Herbal medications |
RF |
|
20623770 |
1802 |
Multiple System Atrophy |
Medical methods |
Medicines |
|
Human |
Herbal medications |
RF |
|
20623770 |
514 |
Amyotrophic Lateral Sclerosis |
Medical methods |
Medicines |
|
Human |
Immunosuppressive drugs |
PF |
|
25059395 |
2733 |
Alzheimer's Disease |
Medical methods |
Medicines |
Neuroleptics |
Human |
inappropriate use anti-dementia drugs |
RF |
|
32251456 |
2155 |
Alzheimer's Disease |
Medical methods |
Medicines |
Neuroleptics |
Human |
irregular medication use anti-dementia drugs |
RF |
|
32251456 |
1882 |
Parkinson disease |
Medical methods |
Medicines |
Antihypertensive |
Human |
metoprolol |
RF |
|
34598055 |
3889 |
Tuberous sclerosis complex |
Medical methods |
Medicines |
|
Human |
multiple antiepileptic drugs |
RF |
|
33225634 |
566 |
Alzheimer's Disease |
Medical methods |
Medicines |
Analgesic and anti-inflammatory drugs |
Human |
no chronic use of nonsteroidal anti-inflammatory drugs |
PF |
|
18446027 |
392 |
Alzheimer's Disease |
Medical methods |
Medicines |
Analgesic and anti-inflammatory drugs |
Human |
Non-aspirin NSAIDS |
PF |
|
33435977 |
373 |
Parkinson disease |
Medical methods |
Medicines |
Analgesic and anti-inflammatory drugs |
Human |
Non-aspirin NSAIDS |
PF |
|
33435977 |
400 |
Parkinson disease |
Medical methods |
Medicines |
|
Human |
non-hydroxychloroquine immunosuppressant therapy |
PF |
Sj?gren syndrome (SS) |
30946325 |
702 |
Amyotrophic Lateral Sclerosis |
Medical methods |
Medicines |
contraceptive pills |
Human |
OCP(oral contraceptive) |
PF |
female |
28835399 |
2930 |
Amyotrophic Lateral Sclerosis |
Medical methods |
Medicines |
contraceptive pills |
Human |
OCP(oral contraceptive) |
RF |
postmenopausal |
37493444 |
1777 |
Parkinson disease |
Medical methods |
Medicines |
Gastrointestinal drugs |
Human |
Proton pump inhibitors (PPIs) |
RF |
1-year lag period was applied between PPI exposure and PD development |
38096177 |
3499 |
Alzheimer's Disease |
Medical methods |
Medicines |
Gastrointestinal drugs |
Human |
Proton pump inhibitors (PPIs) |
RF |
Chronic consumption of PPIs |
20456731 |
469 |
Alzheimer's Disease |
Medical methods |
Medicines |
Statin |
Human |
Statin therapy |
PF |
|
32753051 |
2478 |
Parkinson disease |
Medical methods |
Medicines |
Statin |
Human |
statin use |
RF |
|
34347020 |
897 |
Parkinson disease |
Medical methods |
Medicines |
Statin |
Human |
statin use |
PF |
|
34275907 |
817 |
Alzheimer's Disease |
Medical methods |
Medicines |
Statin |
Human |
statin use |
PF |
|
33804752 |
398 |
Alzheimer's Disease |
Medical methods |
Medicines |
Statin |
Human |
statin use |
PF |
|
20533968 |
735 |
Multiple System Atrophy |
Medical methods |
Medicines |
Analgesic and anti-inflammatory drugs |
Human |
use of non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) |
PF |
|
31661696 |
766 |
Multiple System Atrophy |
Medical methods |
Medicines |
Analgesic and anti-inflammatory drugs |
Human |
use of non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) |
PF |
Cumulative doses were used to divide observations into tertiles creating 3 groups of equal size (T1–3) based on the consumption in defined daily dose(DDD) with T1 representing the group with the lowest use and T3 the highest. |
31661696 |
645 |
Multiple System Atrophy |
Medical methods |
Medicines |
Analgesic and anti-inflammatory drugs |
Human |
use of non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) |
PF |
Cumulative doses were used to divide observations into tertiles creating 3 groups of equal size (T1–3) based on the consumption in DDDs with T1 representing the group with the lowest use and T3 the highest. |
31661696 |
583 |
Amyotrophic Lateral Sclerosis |
Medical methods |
Medicines |
Statin |
Human |
Use of statins |
PF |
|
25059395 |
1993 |
Amyotrophic Lateral Sclerosis |
Medical methods |
Medicines |
Statin |
Human |
Use of statins |
RF |
|
32097525 |
803 |
Parkinson disease |
Medical methods |
Medicines |
|
Human |
β-agonists |
PF |
|
34598055 |
1940 |
Parkinson disease |
Medical methods |
Medicines |
|
Human |
β-antagonists |
RF |
|
34598055 |
361 |
Progressive Supranuclear Palsy |
Medical methods |
Medicines |
Analgesic and anti-inflammatory drugs |
Human |
Non-steroidal anti-inflammatory drug (except
aspirin) |
Not Related |
|
19864660 |
539 |
Parkinson disease |
Medical methods |
Medicines |
Analgesic and anti-inflammatory drugs |
Human |
Aspirin |
PF |
|
34494887 |
360 |
Progressive Supranuclear Palsy |
Medical methods |
Medicines |
Analgesic and anti-inflammatory drugs |
Human |
Aspirin |
Not Related |
|
19864660 |
1125 |
Multiple System Atrophy |
Medical methods |
Medicines |
Analgesic and anti-inflammatory drugs |
Human |
Aspirin |
PF |
|
18307243 |
359 |
Progressive Supranuclear Palsy |
Medical methods |
Medicines |
Analgesic and anti-inflammatory drugs |
Human |
Anti-inflammatory agent |
Not Related |
|
19864660 |
1325 |
Parkinson disease |
Medical methods |
Medicines |
Asthma drugs |
Human |
β2-agonists |
PF |
|
30311974 |
1324 |
Parkinson disease |
Medical methods |
Medicines |
Asthma drugs |
Human |
β2-agonists |
PF |
|
30311974 |
1323 |
Parkinson disease |
Medical methods |
Medicines |
Asthma drugs |
Human |
β2-agonists |
PF |
|
30311974 |
4372 |
Parkinson disease |
Medical methods |
Medicines |
|
Human |
Propranolol |
RF |
|
30311974 |
2237 |
Parkinson disease |
Medical methods |
Medicines |
|
Human |
Propranolol |
RF |
|
34598055 |
4373 |
Parkinson disease |
Medical methods |
Medicines |
|
Human |
Propranolol |
RF |
|
30311974 |
1321 |
Parkinson disease |
Medical methods |
Medicines |
Antidiabetic |
Human |
Glitazone(GTZ) |
PF |
People with diabetes |
28861893 |
4370 |
Parkinson disease |
Medical methods |
Medicines |
Neuroleptics |
Human |
Methamphetamine/amphetamine abuse |
RF |
(ICD-9-CM 304.4, 305.7, 969.7, E854.2) |
25479916 |
4369 |
Parkinson disease |
Medical methods |
Medicines |
hypnagogue |
Human |
Zolpidem |
RF |
Zolpidem use in patients with sleep disturbance |
25124550 |
4368 |
Parkinson disease |
Medical methods |
Medicines |
hypnagogue |
Human |
Zolpidem |
RF |
Zolpidem use in patients with sleep disturbance |
25124550 |
1320 |
Parkinson disease |
Medical methods |
Medicines |
Antihypertensive |
Human |
ARBs(angiotensin receptor blockers) |
PF |
Antihypertensive agents |
24910980 |
1319 |
Parkinson disease |
Medical methods |
Medicines |
Antihypertensive |
Human |
ACEIs(angiotensin converting enzyme inhibitors) |
PF |
Antihypertensive agents |
24910980 |
1318 |
Parkinson disease |
Medical methods |
Medicines |
Antihypertensive |
Human |
CCB(calcium channel blockers) |
PF |
Antihypertensive agents ;Centrally-acting dihydropyridine CCB use |
24910980 |
4367 |
Parkinson disease |
Medical methods |
Medicines |
Neuroleptics |
Human |
Benzamides |
RF |
Neuroleptics |
23019267 |
4366 |
Parkinson disease |
Medical methods |
Medicines |
Neuroleptics |
Human |
Phenothiazines |
RF |
Neuroleptics |
23019267 |
4365 |
Parkinson disease |
Medical methods |
Medicines |
Neuroleptics |
Human |
Neuroleptics |
RF |
All Neuroleptics |
23019267 |
4363 |
Parkinson disease |
Medical methods |
Medicines |
|
Human |
Polypharmacy |
RF |
|
21951955 |
4362 |
Parkinson disease |
Medical methods |
Medicines |
|
Human |
Polypharmacy |
RF |
|
21951955 |
2131 |
Alzheimer's Disease |
Medical methods |
Medicines |
|
Human |
Polypharmacy |
RF |
|
32251456 |
4364 |
Parkinson disease |
Medical methods |
Medicines |
|
Human |
Polypharmacy |
RF |
|
21951955 |
4361 |
Parkinson disease |
Medical methods |
Medicines |
|
Human |
Polypharmacy |
RF |
|
21951955 |
1315 |
Parkinson disease |
Medical methods |
Medicines |
Analgesic and anti-inflammatory drugs |
Human |
Ibuprofen |
PF |
There was a dose-response relationship between tablets of ibuprofen taken per week and PD risk (p trend = 0.01). |
21368281 |
1313 |
Parkinson disease |
Medical methods |
Medicines |
Antihypertensive |
Human |
L-type calcium channel blockers |
PF |
|
20437557 |
1312 |
Parkinson disease |
Medical methods |
Medicines |
Antihypertensive |
Human |
Antihypertensives(Calcium channel blockers) |
PF |
|
18256367 |
4188 |
Creutzfeldt-Jakob disease |
Medical methods |
Medicines |
|
Human |
Medication |
RF |
|
19144172 |
1076 |
Alzheimer's Disease |
Medical methods |
Medicines |
Statin |
Human |
Atorvastatin |
PF |
|
15974900 |
68 |
Alzheimer's Disease |
Medical methods |
Medicines |
Statin |
Human |
Simvastatin |
Not Related |
|
21795660 |
343 |
Parkinson disease |
Medical methods |
Medicines |
Analgesic and anti-inflammatory drugs |
Human |
NSAIDs |
Not Related |
|
17851257 |
66 |
Alzheimer's Disease |
Medical methods |
Medicines |
Analgesic and anti-inflammatory drugs |
Human |
NSAIDs |
Not Related |
|
18519870 |
67 |
Alzheimer's Disease |
Medical methods |
Medicines |
Analgesic and anti-inflammatory drugs |
Human |
NSAIDs |
Not Related |
|
10192221 |
1788 |
Parkinson disease |
Medical methods |
Medicines |
Statin |
Human |
Statin |
RF |
hyperlipidemia |
35276584 |
1774 |
Parkinson disease |
Medical methods |
Medicines |
Statin |
Human |
Statin |
RF |
hyperlipidemia |
35276584 |
378 |
Alzheimer's Disease |
Medical methods |
Medicines |
Statin |
Human |
Statin |
PF |
|
33435977 |
1079 |
Alzheimer's Disease |
Medical methods |
Medicines |
Statin |
Human |
Statin |
PF |
|
20533968 |
1317 |
Parkinson disease |
Medical methods |
Medicines |
Statin |
Human |
Statin |
PF |
Statin treatment |
24304212 |
1314 |
Parkinson disease |
Medical methods |
Medicines |
Statin |
Human |
Statin |
PF |
Short-term (
20629142 |
|
1078 |
Alzheimer's Disease |
Medical methods |
Medicines |
Statin |
Human |
Statin |
PF |
|
18931004 |
1075 |
Alzheimer's Disease |
Medical methods |
Medicines |
Statin |
Human |
Statin |
PF |
|
25408208 |
1316 |
Parkinson disease |
Medical methods |
Medicines |
Statin |
Human |
Statin |
PF |
|
22410446 |
1080 |
Alzheimer's Disease |
Medical methods |
Medicines |
Statin |
Human |
Statin |
PF |
|
19595865 |
384 |
Parkinson disease |
Medical methods |
Medicines |
Statin |
Human |
Statin |
PF |
|
33435977 |
1077 |
Alzheimer's Disease |
Medical methods |
Medicines |
Statin |
Human |
Statin |
PF |
|
14739574 |